Nivolumab Crt Improves Dfs In

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO's chief medical officer, on the results of the NIVOPOSTOP trial, ... Ari Rosenberg, MD, University of Chicago, Chicago, IL, describes the trial design of the Phase II DEPEND trial (NCT03944915), ... Heather A. Wakelee, MD, Stanford University, Stanford, CA, talks on the findings of IMpower010, a Phase III global study of ... Dr Eroglu talks to ecancer at ASCO 2025 about data she presented from the SWOG S2000 phase II trial. This is the first ... Martin H. Voss, MD, medical oncologists, Memorial Sloan Kettering Cancer Center, reviews the method of design and results for ... Van Morris, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents findings from the Phase II SWOG ...

Matthew Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses results from a Phase I/II study (NCT03172754) ... Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, comments on the future direction of Hodgkin lymphoma ... Yana Najjar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses a Phase II trial (NCT04493203) of John Strickler, MD, Duke University, Durham, NC, gives an overview of the Phase III CheckMate 8HW trial (NCT04008030), which ... Scott Haake, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, discusses the efficacy of cabozantinib and Nadine Abi-Jaoudeh, MD, University of California, Irvine, CA, comments on a Phase II study (NCT04472767) evaluating ...

Elizabeth Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, gives an overview of results from a Phase I/II study ...